Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lucinactant for inhalation versus nCPAP alone in preterm neonates with respiratory distress syndrome
NL-OMON43417Phase 2Active, not recruiting
- Sponsor
- Windtree Therapeutics, Inc.
- Start
- Dec 2016
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of lucinactant in respiratory distress syndrome (RDS) (2 arms), sponsored by Windtree Therapeutics, Inc. Primary endpoint: Time to respiratory failure or death due to respiratory distress syndrome within the first 72 hours of life. Started Dec 2016; status: active, not recruiting.
02
Drugs
lucinactant
03
Conditions
respiratory distress syndrome (RDS)
Beyond the preview
Go deeper on NL-OMON43417.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43417.